CompletedPhase 3

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

United States515 participantsStarted 2019-02-28

Plain-language summary

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment. Exclusion Criteria: * Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study. * Previous administration with Bimatoprost SR in the study eye.

What they're measuring

Retreatment or rescue administered for IOP

Timeframe: Up to 48 months

Number of patients experiencing a treatment emergent adverse event

Timeframe: Baseline up to 48 months

Trial details

NCT IDNCT03850782

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-08-08

View on ClinicalTrials.gov More Open-Angle Glaucoma trials